Climate change-driven extreme weather events threaten the pharmaceutical supply chain in the U.S., with 62.8% of facilities in disaster-prone counties, finds new research.
The review extension follows FDA observations at a former Catalent facility now owned by Novo Nordisk, which handles final preparation and packaging of Eylea HD.
